Garg Ravi, Torrealba-Acosta Gabriel, Mandava Pitchaiah
Silver Cross Neuroscience Institute, New Lennox, IL, USA.
Division of Neurocritical Care, Department of Neurology, Duke University, Durham, NC, USA.
Neurocrit Care. 2025 Sep 4. doi: 10.1007/s12028-025-02350-w.
Recent American Heart Association guidelines have relied on post hoc subgroup analyses to identify summary blood pressure measures for targets in early management of acute intracerebral hemorrhage. To our knowledge, measurement error has not been considered when determining the impact of these summary measures. Our objective was to determine whether statistically significant differences in three systolic blood pressure (SBP) measures (achieved SBP, SBP variability, and magnitude of SBP reduction) in patients with intracerebral hemorrhage from the antihypertensive treatment of acute cerebral hemorrhage II (ATACH-2) randomized clinical trial are clinically meaningful by comparing them to a minimally detectable difference (MDD) of 10 mm Hg.
We performed a post hoc analysis of individual patient data from the ATACH-2 randomized clinical trial, evaluating the differences in achieved SBP, SBP variability, and magnitude of SBP reduction between patients with favorable (modified Rankin scale score 0-3) and unfavorable (modified Rankin scale score 4-6) outcomes. We used the empirical cumulative distribution functions and Kolmogorov-Smirnov tests to compare distributions, and we considered differences clinically meaningful if they exceeded the MDD of 10 mm Hg. We also performed a propensity score matched analysis to understand the nature of the association between these measures and outcomes.
Although SBP variability in the first 24 h differed statistically between outcome groups, the mean difference (95% confidence interval) did not exceed the MDD threshold. Achieved SBP and magnitude of SBP reduction showed no significant differences between groups. In the propensity score matched analysis, there were no statistical differences between any blood pressure measurements and outcomes.
Our findings suggest that although there are statistically significant differences in SBP variability between patients with good and poor outcomes in ATACH-2, these differences do not meet the threshold for clinical relevance because they were within the range of measurement noise. The propensity score matched analysis suggested that the association between summary blood pressure measurements and outcomes is not robust to analytical method. These findings emphasize the need for caution in interpreting post hoc findings for clinical decision-making.
美国心脏协会近期的指南依赖事后亚组分析来确定急性脑出血早期管理目标的汇总血压测量值。据我们所知,在确定这些汇总测量值的影响时未考虑测量误差。我们的目的是通过将急性脑出血降压治疗II(ATACH - 2)随机临床试验中脑出血患者的三种收缩压(SBP)测量值(达到的SBP、SBP变异性和SBP降低幅度)与10 mmHg的最小可检测差异(MDD)进行比较,来确定这些差异在临床上是否有意义。
我们对ATACH - 2随机临床试验的个体患者数据进行了事后分析,评估预后良好(改良Rankin量表评分0 - 3)和预后不良(改良Rankin量表评分4 - 6)的患者在达到的SBP、SBP变异性和SBP降低幅度方面的差异。我们使用经验累积分布函数和Kolmogorov - Smirnov检验来比较分布,如果差异超过10 mmHg的MDD,我们认为差异具有临床意义。我们还进行了倾向评分匹配分析,以了解这些测量值与预后之间关联的性质。
尽管前24小时内SBP变异性在不同预后组之间存在统计学差异,但平均差异(95%置信区间)未超过MDD阈值。达到的SBP和SBP降低幅度在组间无显著差异。在倾向评分匹配分析中,任何血压测量值与预后之间均无统计学差异。
我们的研究结果表明,尽管在ATACH - 2中预后良好和不良的患者之间SBP变异性存在统计学显著差异,但这些差异未达到临床相关性阈值,因为它们处于测量噪声范围内。倾向评分匹配分析表明,汇总血压测量值与预后之间的关联对分析方法不稳健。这些发现强调在将事后研究结果用于临床决策时需谨慎。